CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
April 5 (Reuters) - The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson (JNJ.N), opens new tab and Legend Biotech's (LEGN.O), opens new tab Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.
Legend and Johnson & Johnson have expanded a previous manufacturing agreement with Novartis to perform commercial production of CAR-T drug Carvykti.
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
CARVYKTI Receives Recommendation from FDA Oncologic Drugs Advisory Committee
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results
Legend CEO offers preview of high-stakes FDA adcomm for Carvykti
EMA recommends approval of Carvykti in earlier lines of multiple myeloma